Arbutus Biopharma (ABUS) Revenue (2013 - 2026)

Arbutus Biopharma (ABUS) has 14 years of Revenue data on file, last reported at $179.1 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 10054.54% year-over-year to $179.1 million; the trailing twelve-month figure through Mar 2026 stood at $191.4 million (up 2889.93% YoY), and the FY2025 full-year result was $14.1 million, up 128.21% from the prior year.
• Revenue advanced to $179.1 million in Q1 2026, from $1.1 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $179.1 million in Q1 2026 to a low of $529000.0 in Q3 2025.
• A 5-year average of $15.1 million and a median of $4.7 million in 2023 frame the typical range for Revenue.
• Across the five-year window, Revenue plunged 77.09% in 2024 and surged 10054.54% in 2026, its largest moves.
• Tracing ABUS's Revenue over 5 years: stood at $6.2 million in 2022, then tumbled by 65.65% to $2.1 million in 2023, then dropped by 26.62% to $1.6 million in 2024, then slumped by 33.23% to $1.1 million in 2025, then jumped by 16943.39% to $179.1 million in 2026.
• Business Quant data shows ABUS's Revenue at $179.1 million in Q1 2026, $1.1 million in Q4 2025, and $529000.0 in Q3 2025.